5yr
Immune checkpoint inhibitors combined with chemotherapy/bevacizumab therapy for patients with advanced lung cancer and heavily treated with EGFR mutation: a retrospective analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34164187/
Background: EGFR-mutated lung cancer poorly responded to anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) monotherapy. Whether patients with EGFR-mutated lung cancer can benefit from anti-PD-1/PD-L1 therapy combined with other drugs remains controversial.
Key Points
• In the current study, researchers retrospectively assessed whether 56 patients with EGFR-mutated lung cancer were effectively be treated with PD-1/PD-L1 therapy plus chemotherapy with or without bevacizumab. These patients had previously received extensive treatment and progressed on EGFR-TKI treatment.
• The authors documented objective responses in 10.7% of patients. Disease was controlled in 53.6% of patients, and the median PFS was months, with no patient exhibiting complete response.
• “Results show that the PD-1 inhibitor-based combination therapy and the EGFR wild-type lung cancer have similar AE [adverse event] profiles,” the authors wrote. “This combination therapy shows longer PFS than the PD-1 inhibitor monotherapy reported before. However, the addition of chemotherapy and/or bevacizumab therapy to the anti-PD-1 therapy did not remarkably improved on heavily treated patients.”